Early Interleukin-22 and Neutrophil Proteins Are Correlated to Future Lung Damage in Children With Cystic Fibrosis

Julie Renwick1, Emma Reece1, Jamie Walsh2

  • 1Clinical Microbiology, Trinity College Dublin, Dublin, Ireland.

Insights

Early life neutrophil protein levels in Cystic Fibrosis (CF) infants may predict later lung damage. Specific proteins like azurocidin and myeloperoxidase showed positive correlations, while others like Complement C3 showed negative correlations with lung damage scores.

Area of Science:

  • Pulmonary Medicine
  • Biomarker Discovery
  • Immunology

Background:

  • Cystic Fibrosis (CF) lung damage initiates early, linked to infections and inflammation.
  • Neutrophils in CF patients exhibit an altered phenotype, suggesting early dysfunction.
  • Predicting disease progression is crucial for timely therapeutic interventions.

Purpose of the Study:

  • To identify early life signals of dysfunctional neutrophil responses in CF.
  • To determine if these early signals correlate with lung damage in later childhood.

Main Methods:

  • Pulmonary protein profiles of 14 stable CF infants and pre-schoolers analyzed using SOMAscan®.
  • High-resolution computed tomography (HRCT) and Brody score calculated after age 6.
  • Spearman's rank correlation and Benjamini-Hochberg adjustment used for analysis.

Main Results:

  • Early azurocidin and myeloperoxidase levels positively correlated with later Brody scores (p=0.0041, p=0.0182).
  • Complement C3, X-ray repair CCP 6, C3a anaphylatoxin des Arginine, and cytokine receptor common subunit gamma negatively correlated with Brody scores.
  • Lower early IL-22 levels were associated with more severe lung damage (p=0.0243).

Conclusions:

  • Early life pulmonary protein profiles, particularly neutrophil-associated proteins, may serve as biomarkers for predicting CF lung damage progression.
  • IL-22 warrants further investigation for its role in CF pathogenesis.
  • Findings highlight the potential for early therapeutic interventions based on identified biomarkers.